Loading…

Defining bottlenecks and opportunities for Lassa virus neutralization by structural profiling of vaccine-induced polyclonal antibody responses

Lassa fever continues to be a major public health burden in West Africa, yet effective therapies or vaccines are lacking. The isolation of protective neutralizing antibodies against the Lassa virus glycoprotein complex (GPC) justifies the development of vaccines that can elicit strong neutralizing a...

Full description

Saved in:
Bibliographic Details
Published in:Cell reports (Cambridge) 2024-09, Vol.43 (9), p.114708, Article 114708
Main Authors: Brouwer, Philip J.M., Perrett, Hailee R., Beaumont, Tim, Nijhuis, Haye, Kruijer, Sabine, Burger, Judith A., Bontjer, Ilja, Lee, Wen-Hsin, Ferguson, James A., Schauflinger, Martin, Müller-Kräuter, Helena, Sanders, Rogier W., Strecker, Thomas, van Gils, Marit J., Ward, Andrew B.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lassa fever continues to be a major public health burden in West Africa, yet effective therapies or vaccines are lacking. The isolation of protective neutralizing antibodies against the Lassa virus glycoprotein complex (GPC) justifies the development of vaccines that can elicit strong neutralizing antibody responses. However, Lassa vaccine candidates have generally been unsuccessful at doing so, and the associated antibody responses to these vaccines remain poorly characterized. Here, we establish an electron microscopy-based epitope mapping workflow that enables high-resolution structural characterization of polyclonal antibodies to the GPC. By applying this method to rabbits vaccinated with a recombinant GPC vaccine and a GPC-derived virus-like particle, we reveal determinants of neutralization that involve epitopes of the GPC-A competition cluster. Furthermore, by identifying undescribed immunogenic off-target epitopes, we expose the challenges that recombinant GPC vaccines face. By enabling detailed polyclonal antibody characterization, our work ushers in a next generation of more rational Lassa vaccine design. [Display omitted] •Tyrosine sulfation is employed by mAb 8.9F to target the GPC apex•Polyclonal epitopes of immunized rabbits are mapped using electron microscopy•Recombinant GPC elicits off-target responses aimed at the trimer base and interior•VLP-embedded GPC elicits responses closely resembling neutralizing mAbs Brouwer et al. develop a pipeline to map polyclonal antibody responses to the Lassa virus glycoprotein using electron microscopy. By applying this to serum from rabbits vaccinated with different vaccine modalities, they reveal and structurally characterize vaccine-specific off- and on-target antibody responses to the Lassa virus glycoprotein.
ISSN:2211-1247
2211-1247
DOI:10.1016/j.celrep.2024.114708